BMS-777607: Precision c-Met Inhibition for Translational Research

Principle Overview: Harnessing Selectivity in MET Signaling Pathway Inhibition

BMS-777607 is a highly selective, ATP-competitive inhibitor targeting the MET kinase family—most notably c-Met, Axl, Ron, and Tyro3. Its sub-nanomolar potency (e.g., IC50 = 3.9 nM for c-Met) and robust selectivity profile make it an indispensable tool for dissecting the MET signaling pathway in oncology and stem cell biology [product_spec]. Mechanistically, BMS-777607 impairs c-Met auto-phosphorylation, thereby attenuating downstream cascades that drive tumor growth, metastasis, and cellular differentiation [source_link]. Its oral bioavailability and performance in both in vitro and in vivo models further distinguish it among c-Met inhibitors for research applications.

Step-by-Step Workflow: Integrating BMS-777607 into Experimental Protocols

Researchers leverage BMS-777607 in a spectrum of experimental workflows, from cancer metastasis models to induced pluripotent stem cell (iPSC) differentiation. Its use is particularly prominent in:

• Cancer Metastasis Modeling: In murine KHT xenograft models, BMS-777607 administered at 25 mg/kg/day by oral gavage significantly reduced lung tumor nodules by 28.3%, improving tumor morphology without systemic toxicity [source_type: paper | source_link].
• Polyploidy Induction in Megakaryocytes: As highlighted in the reference study, small-molecule kinase inhibitors like BMS-777607 are incorporated during hiPSC differentiation to enhance megakaryocyte polyploidization, a critical step for functional platelet production [source_type: paper | source_link].
• Pathway Dissection: The compound’s selectivity enables clean interrogation of MET pathway dependencies in apoptosis and metastasis suppression workflows [source_type: paper | source_link].

Protocol Parameters

• assay: In vitro kinase inhibition | value_with_unit: 10 μM BMS-777607 | applicability: abolishes basal c-Met autophosphorylation in murine KHT cells | rationale: Ensures potent MET pathway inhibition in cell-based assays | source_type: product_spec [source_link]
• assay: In vivo xenograft efficacy | value_with_unit: 25 mg/kg/day oral gavage | applicability: Reduces lung tumor nodules by 28.3% in KHT mouse models | rationale: Validated dose for metastasis suppression with minimal toxicity | source_type: paper [source_link]
• assay: MK polyploidization during hiPSC differentiation | value_with_unit: BMS-777607 at 1–10 μM, 37°C, 3–5 days | applicability: Enhances megakaryocyte maturation and functional platelet yield | rationale: Supports optimized ex vivo thrombopoiesis protocols | source_type: workflow_recommendation [source_link]

Key Innovation from the Reference Study

The study “Optimizing the Method for Differentiation of Functional Platelets from Human Induced Pluripotent Stem Cells” introduced a multi-faceted differentiation protocol that enhances ex vivo platelet yield and reduces production costs. By systematically integrating small molecules—including BMS-777607—into the polyploidization phase, the protocol shortens differentiation to 19 days and achieves a yield of 14.9 platelets per iPSC, while cutting costs by 58.3% [source_type: paper | source_link]. For researchers, this means BMS-777607 can be directly applied to drive megakaryocyte maturation and polyploidization, streamlining the generation of functional, high-yield platelets for cell therapy and gene editing workflows.

Comparative Advantages and Advanced Applications

BMS-777607 stands out among c-Met inhibitors for its exceptional selectivity—exhibiting approximately 40-fold preference over kinases such as Lck, VEGFR-2, and TrkA/B, and over 500-fold selectivity compared to other kinases [source_type: product_spec | source_link]. This fine-tuned specificity ensures minimal off-target effects in complex biological systems, making it ideal for:

• Cancer Metastasis Models: Enables researchers to dissect MET-dependent versus MET-independent pathways in tumor progression and metastasis suppression [source_type: paper | source_link].
• Stem Cell Differentiation: Facilitates robust polyploidization in megakaryocyte lineage, as shown in optimized hiPSC protocols [source_type: paper | source_link].
• Prostate Cancer Research: The compound’s pathway inhibition properties have been extended to prostate cancer models requiring precise MET signaling modulation [source_type: workflow_recommendation | source_link].

For a broader strategic perspective, see the interlinked article “BMS-777607: Mechanistic Precision and Strategic Value for...”, which complements this guide by providing detailed bio-rationale and workflow integration advice. In contrast, “Strategic Inhibition of MET Signaling: BMS-777607 as a Translational Bridge” extends the discussion into the future of tyrosine kinase research, while “Translational Synergy: Leveraging BMS-777607 for Advanced Models” provides actionable guidance on assay design and workflow troubleshooting. Together, these resources form a comprehensive knowledge base for translational scientists.

Troubleshooting and Optimization Tips

• Solubility Management: BMS-777607 is highly soluble in DMSO (≥25.65 mg/mL) but insoluble in water or ethanol. Warm the solution to 37°C and sonicate if needed for complete dissolution [source_type: product_spec | source_link]. Avoid prolonged storage of dissolved stocks; prepare fresh aliquots at -20°C for best results.
• Dose Titration: Begin with 1–10 μM concentrations for in vitro work, and titrate upward only if needed based on pathway readouts (e.g., c-Met phosphorylation status by immunoblot). For in vivo, adhere strictly to 25 mg/kg/day unless otherwise validated [source_type: workflow_recommendation | source_link].
• Assay Timing and Readout: When used in differentiation protocols, introduce BMS-777607 during the polyploidization phase (typically day 10–14 in hiPSC protocols) and assess megakaryocyte maturation via flow cytometry or microscopy after 3–5 days [source_type: paper | source_link].
• Off-Target Monitoring: While highly selective, confirm absence of off-target effects via kinase panel or phospho-protein profiling in your system, especially if combining BMS-777607 with other small molecules [source_type: workflow_recommendation].
• Shipping and Storage: For best stability, order BMS-777607 from APExBIO with blue ice shipping, and store powder at -20°C upon receipt [source_type: product_spec | source_link].

Why this Cross-Domain Matters, Maturity, and Limitations

The successful application of BMS-777607 in both oncology and stem cell-derived platelet production is grounded in the shared reliance on MET signaling for cellular proliferation, differentiation, and migration. The reference study's demonstration of enhanced megakaryocyte maturation via kinase pathway inhibition directly bridges cancer biology with regenerative medicine [source_type: paper | source_link]. However, while in vitro and murine in vivo data are robust, further work is needed before translation to clinical-grade protocols or human therapy—underscoring the importance of rigorous validation and safety testing.

Future Outlook

Emerging evidence positions BMS-777607 as a cornerstone for MET pathway interrogation and applied translational research. Its proven efficacy in cancer metastasis models, coupled with its newfound role in efficient platelet production from hiPSCs, signals a paradigm shift for researchers seeking cost-effective, high-yield, and mechanistically precise tools. APExBIO’s quality assurance and supply reliability further cement BMS-777607 as a top choice for reproducible research. As protocols mature, researchers should continue to cross-validate findings across domains, leveraging BMS-777607 to advance both cancer biology and regenerative medicine within ethically and scientifically rigorous frameworks.